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In this mini-review, we highlight selected research by the Deutsche Forschungsgemeinschaft
(DFG) Cluster of Excellence “Precision Medicine in Chronic Inflammation” focusing on clinical
sequencing and the clinical utility of polygenic risk scores as well as its implication on precision
medicine in the field of the inflammatory diseases inflammatory bowel disease, atopic
dermatitis and coronary artery disease. Additionally, we highlight current developments and
discuss challenges to be faced in the future. Exemplary, we point to residual challenges in
detecting disease-relevant variants resulting from difficulties in the interpretation of candidate
variants and their potential interactions. While polygenic risk scores represent promising tools
for the stratification of patient groups, currently, polygenic risk scores are not accurate enough
for clinical setting. Precision medicine, incorporating additional data from genomics,
transcriptomics and proteomics experiments, may enable the identification of distinct
disease pathogeneses. In the future, data-intensive biomedical innovation will hopefully lead
to improved patient stratification for personalized medicine.
Keywords: inflammation, atopic dermatitis, inflammatory bowel disease, coronary artery disease, genome-wide
association studies, polygenic risk score, whole-exome sequencingINTRODUCTION
Since sequencing-based high throughput methods have led to cost-effective sequencing of big
patient cohorts, our understanding of the genetic background of diseases has evolved. But the more
data we are accumulating, the more we understand how complex the genetic background of some
diseases is. In chronic inflammatory diseases, such as inflammatory bowel disease (IBD), atopic
dermatitis (AD) and coronary artery disease (CAD), research has revealed a number of risk loci that
are involved in disease pathophysiology. In spite of the growing number of identified genetic risk
genes, functional targeted therapies evolving from our newfound genetic understanding are still inorg January 2021 | Volume 11 | Article 5776771
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that can lead to complex inflammatory disease. Which variants
lead to a phenotype? Which combinations of variations, but not
single variants lead to a combined effect that causes physiological
impairments? Are patient cohorts where genetic information is
derived from predictive for individual patients? And even if we
can pinpoint a causative variant, can patients profit from this?
With the rise of high-throughput methods in sequencing we
stand on the brink of a revolution in precision medicine. We
deepen our understanding of the genetic background that
underlies disease on an individual basis and with this we, for
the first time, have the tools to implement therapies that
distinguish disease subtypes but likewise optimize drug efficacy
and minimize side effects. Clinical sequencing for precision
medicine can be applied on several levels. Primarily,
sequencing provides basic information and with this a
characterization of the genetic background of disease. On a
second level, genetic information can lead to the generation of
prospective knowledge of disease risk, disease severity and
disease outcomes. Moreover, sequencing can lead to the
identification of subtypes of the disease based on their
genetical characteristics.
IBD, AD and CAD represent multifactorial disorders, with
genetic as well as environmental factors contributing to the
respective clinical phenotype. The complex genetics of these
diseases has been comprehensively studied. However, our current
understanding of their etiology is still limited. Various studies
based on national health registries report an association between
the diagnoses of AD and IBD, suggesting a shared pathophysiology.
Indeed, e.g., increased TH1/TH17 signaling and the resulting
secretion of proinflammatory cytokines represent mutual
hallmarks of these diseases (1–3). Likewise, there is evidence for
IBD patients to be at an increased risk of atherosclerosis and,
consequently, an increased risk for cardiovascular diseases,
including CAD. Postulated pathological links between the
diseases are manyfold and include the deregulation of
inflammatory mediators, dysfunction of endothelial barriers as
well as effects of gut microbial endotoxins (4–7).Abbreviations: AD, atopic dermatitis; ANGPTL4, angiopoietin-like 4; APOB,
apolipoprotein B-100; ATG16L1, autophagy related 16 like 1; AUC, area under the
ROC curve; CAD, coronary artery disease; CD, Crohn’s disease; CD200R1, cell
surface glycoprotein CD200 receptor 1; DOK2, docking protein 2; EDC, epidermal
differentiation complex; eoIBD, early-onset IBD; FH, familial hypercholesteremia;
FLG, Profilaggrin; FLG2, filaggrin-2; GPRS, genetic profile risk scores; GWAS,
genome-wide association studies; HLA, Human leukocyte antigen; HLA-DRB1,
HLA class II, histocompatibility antigen, DRB1 beta chain; HMG-CoA reductase,
3-hydroxy-3-methyl-glutaryl-coenzyme A reductase; HSCT, hematopoetic stem
cell transplant; IBD, inflammatory bowel disease; IBD-U, IBD unclassified; IL10R,
interleukin 10 receptor; IL23R, interleukin-23 receptor; IRGM, immunity-related
GTPase family M; LDLC, low density lipoprotein cholesterol; LDLR, LDL
receptor; LRRC32, Leucine Rich Repeat Containing 32; MAF, minor allele
frequency; MI, myocardial infarction; NF-kB, nuclear factor ‘kappa-light-chain-
enhancer’ of activated B-cells; NOD1/2, nucleotide-binding oligomerization
domain-containing protein 1/2; PCSK9, proprotein convertase subtilisin/kexin
type 9; PRS, polygenic risk score; RPTN, repetin; SNP, single nucleotide
polymorphism; UC, ulcerative colitis; veoIBD, very-early-onset IBD; WES,
whole-exome sequencing; WHO, world health organization; XIAP, X-linked
inhibitor of apoptosis.
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PROVIDES NEW INSIGHT ON THE
GENETIC BACKGROUND OF
INFLAMMATORY DISEASES
Trio Exome Sequencing Reveals Mono-
and Oligogenic Forms of IBD
Inflammatory bowel diseases are chronic, relapsing disorders
involving inflammation of the gastrointestinal tract caused by the
interplay of an overly active immune system and environmental
triggers in genetically susceptible individuals. The most common
subforms of IBD are Crohn’s disease (CD) and ulcerative colitis
(UC). Hundreds of mostly common susceptibility variants have
been identified through genome-wide association studies
(GWAS), but there are also cases where rare, highly penetrant
variants have a large impact on disease. Early-onset cases of IBD
(eoIBD), with a disease manifestation during the first 10 years of
life, often show a more severe disease course with a higher risk of
complications. Furthermore, they are sometimes affected by
genetically less complex (monogenic or oligogenic) types of the
disease. For example, mutations in genes for the interleukin 10
receptor (IL10R) subunit proteins and the IL10 gene itself have
been shown to be responsible for several cases of severe eoIBD.
Recently, we revealed compound-heterozygosity for a missense
and a synonymous variant affecting splicing in IL10RA in one
patient through trio exome sequencing (8). The XIAP (X-linked
inhibitor of apoptosis) gene has been shown to be responsible for
eoIBD in several male patients. We detected a hemizygous de
novo nonsense mutation in one of our patients resulting in a
selective defect in NOD1/2 signaling (nucleotide-binding
oligomerization domain-containing proteins), impaired NOD1/
2-mediated activation of NF-kB (nuclear factor “kappa-light-
chain-enhancer” of activated B-cells) (9). We also showed a likely
synergistic interaction between a rare hemizygous variant in the
NOX1 (NADPH oxidase) gene and a common homozygous
variant in the CYBA ((Cytochrome B-245 Alpha Chain) gene
altering its antibacterial activity in another veoIBD (very-early-
onset IBD) patient (10). These examples illustrate the benefit of
exome sequencing, and especially trio exome sequencing for
diagnostics in eoIBD patients for the identification of de novo
and compound-heterozygous variants and the reduction of
candidate variants in general.
Association Studies Point to Roles for
Common and Rare Variants in AD
Atopic dermatitis is a complex, polygenic, chronic cutaneous
disorder. With a lifetime prevalence of up to 20% it represents
the most common inflammatory disease of the skin. Atopic
dermatitis is believed to be a cutaneous manifestation of a
systemic disorder that also gives rise to other atopic
conditions, such as asthma and allergic rhinitis. Current
models assume a complex interaction between genetic,
immunological and environmental factors to be involved in the
etiopathogenesis of the disease. For further details, reference is
made to recent reviews (11, 12).January 2021 | Volume 11 | Article 577677
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variants related to the susceptibility for atopic dermatitis (13–
19). In a summarizing meta-analysis Paternoster et al. identified
ten novel risk loci, increasing the number of known loci to 31
(20). The most recent association study of rare protein-coding
variants incorporating genetic data of as much as 15,574 patients
and 377,839 controls resulted in the detection of DOK2 (docking
protein 2) and CD200R1 (cell surface glycoprotein CD200
receptor 1) as additional susceptibility genes (14). Current
estimates of heritabil i ty explained by common AD
susceptibility variants (minor allele frequency MAF≥1%)
amount to 14.91%. An additional 12.56% of heritability are
estimated to be attributable to rare protein-coding variants
(MAF<1%) (21).
Coding regions for major genes of the late epidermal
differentiation have been identified to be colocalized within the
so-called epidermal differentiation complex (EDC). Profilaggrin
(FLG), filaggrin-2 (FLG2), and repetin (RPTN), represent a
subset of EDC gene products contributing to the maturation of
the human epidermis. Mutations of the FLG gene have been
repeatedly shown to be associated with susceptibility and
persistence of AD. However, this association could only be
observed in individuals of European or Asian ancestry. Based
on whole-exome sequencing (WES) mutations of FLG2 (22, 23),
RPTN (24), and CLDN1 (Claudin 1) (25, 26) have been identified
to be associated with susceptibility to AD in patients of non-
European descent. This suggests factors causing dysfunction of
the skin barrier vary across ethnicities (25, 26).
Immunological dysregulation represents another major factor
contributing to the etiology of AD. Human leukocyte antigen
(HLA) genes , such a s HLA-DRB1 (HLA c la s s I I
histocompatibility antigen, DRB1 beta chain), play a crucial
role for the presentation of antigens to the immune system and
have been shown to be associated with the disease. Further
immune abnormalities observed in AD and its common
comorbidities are caused by mutations of the gene LRRC32
(Leucine Rich Repeat Containing 32). Using a targeted
sequencing approach our group identified and validated low-
frequency variants of the gene as strong contributors to AD (27).Heritability of CAD and MI Is Only Partially
Explained by Currently Known Risk Alleles
Atherosclerotic vascular disease and particularly coronary artery
disease remain leading causes of mortality worldwide.
Atherosclerosis is initiated by lipid-mediated damage to the
endothelium, followed by inflammatory cell recruitment and
development of plaques, ultimately leading to plaque erosion or
rupture as well as clinical sequelae such as myocardial infarction
(MI) or stroke. The use of human genetics to reveal causal
mechanisms has proved transformative for deriving aetiological
insights in CAD beyond established concepts.
Rare variant analyses have provided examples on how genetic
discoveries can point to therapeutic approaches for CAD, e.g.,
inhibition of HMG-CoA reductase (3-hydroxy-3-methyl-
glutaryl-coenzyme A reductase) (28), PCSK9 (proprotein
convertase subtilisin/kexin type 9) (29), and ANGPTL4Frontiers in Immunology | www.frontiersin.org 3(angiopoietin-like 4) (30). Genome-wide arrays preferentially
contain single-nucleotide polymorphisms (SNPs) that are
found at a high frequency in a population as those offer the
highest statistical power to detect association. Accordingly,
almost all currently identified 164 risk alleles for CAD are
common (31). Given the large number and the high frequency
of risk alleles that have been identified thus far, virtually every
person in our population carries multiple genetic variants that
increase susceptibility to coronary disease (32). Each risk allele
increases the probability of CAD only by a relatively small
margin, i.e., 5–20 relative percentage points per allele. There
are two exemptions: One low frequency allele on chromosome
6q25.3 tags markedly increased lipoprotein levels and goes along
with a risk increase for coronary disease by 54% (33). The other
one is a relatively common variant on chromosome 9p21.3,
which increases relative risk by 29% (34).
The rapidly growing list of genetic loci associated with
increased risk of CAD is surprising in many aspects.
Exemplary, the majority of them has neither been implied in
the pathogenesis of the disease (35) nor linked to traditional risk
factors (36). Interestingly, the genetic component reflected by
common genetic variants cannot explain familial clustering of
the disease as well. A positive family history rather appears to be
mediated by rare deleterious mutations with a more profound
effect (37–39). Not surprisingly, the heritability of CAD and MI
is only partially explained by currently known risk alleles (35).CLINICAL UTILITY OF POLYGENIC RISK
SCORES
Association Between Polygenic Risk
Scores and Subtypes of IBD
During the past 15 years, GWAS have led to the identification of
more than 200 susceptibility loci for inflammatory bowel disease
(31, 40). Chen et al. (41) utilized this data to perform a
comprehensive comparison of four methods to predict the
genetic risk of IBD. With an area under the ROC curve (AUC)
of up to 0.78 and 0.70 for CD and UC, respectively, the Bayesian
mixture model outperformed the other methods. While this
accuracy is not sufficient for diagnostic use in a clinical setting,
the authors were able to identify significant associations of higher
risk scores with an elevated frequency of bowel resection, earlier
disease onset and ileal disease localization. Similarly, Cutler et al.
observed a statistically significant relationship between a
polygenic liability score and age of onset in pediatric CD
patients (42). Ananthakrishnan et al. employed similar
methods and found an increasing genetic burden to be
associated with earlier age of diagnosis and ileal involvement
in CD patients (43). Likewise, a genetic risk score incorporating
all known IBD risk alleles showed strong association with disease
subphenotypes (44). Predictive models based on this genetic risk
score were able to distinguish between colonic and ileal CD. In
contrast to adult-onset IBD, veoIBD with an age of onset before
the age of six, can be associated with a wide range of rare
monogenic, or Mendelian, disorders, but only in a fraction ofJanuary 2021 | Volume 11 | Article 577677
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effect-size estimates of SNPs significantly associated with adult-
onset CD and UC and analyzed whether veoIBD patients with an
age of onset under the age of six, harbor a higher load of risk
alleles when compared to adult-onset IBD cases or population
controls. The risk scores of veoIBD patients were significantly
higher compared to those of the healthy controls. However, there
was no significant difference between the veoIBD and adult-
onset cases (45). In summary, current literature renders
polygenic risk scores a promising tool for stratifying IBD
patients with regard to age of onset as well as severity of the
disease. Current research, including ongoing work of our group,
tries to further improve the accuracy of PRS-based predictors to
enable future application in a clinical setting.
PRS-Based Stratification by Disease
Susceptibility and Disease Course of AD
Jansen et al. employed additive polygenic risk scores of varying
complexity to investigate the putatively increased susceptibility
of children diagnosed with cow’s milk allergy (CMA) for
common comorbidities, including asthma and AD (46). For
AD the authors detected a decreased PRS independent of the
employed model. PRS-based prediction of further clinical
parameters has been examined in a recent study by Abuabara
et al. (47). In populations of varying ethnicity the authors provide
evidence for a PRS being highly predictive of AD. However,
ancestry-related genetic effects do not independently explain
disparities in disease prevalence and disease control between
the demographic groups under investigation. Clark et al.
investigated the relationship between a PRS and distinct
developmental profiles of eczema, wheeze, and rhinitis
identified using Bayesian machine learning methods (48). The
authors provide evidence for differential association of the PRS
across the entirety of developmental profiles, suggesting
heterogeneous mechanisms underlying individual disease
trajectories. In summary, first studies describe PRS as
promising tools for the stratification of cohorts of AD patient
with regard to their disease susceptibility and disease course.
However, further studies are needed, to replicate these findings.
Estimating CAD Risk Using PRS
Being a polygenic disease with a substantial heritability, CAD is
an attractive target for risk estimation based on the genetic
background. Models for risk estimation have already been
proposed and entered clinical routine, such as the HeartScore
(49) and the Framingham Risk Score (50). However, these are
mainly based on clinical variables. Previously, efforts have been
made to improve existing models by the addition of scores
based on individual genetic variants (51–55). The PRS used in
these approaches were limited by considering only genetic
variants for which an association with CAD had previously
been established. Recently, this limitation has been abolished by
genome-wide polygenic risk scores proposed by Khera et al.
(56) and Inouye et al. (57). Using millions of genetic variants to
predict the risk of CAD and other complex diseases, these
methods outperform model incorporating conventional riskFrontiers in Immunology | www.frontiersin.org 4factors. This suggests genetic risk prediction to enable effective
prevention strategies.
It is arguable that summarizing the genetic risk using an
inherent assumption of linearity is too simple given the complex
biological structure of common diseases. Further, estimating the
weight of each variant by univariate association tests only
neglects possible interactions between variants. Especially in
the MHC region, variants can exhibit non-linear effects on
diseases through interactions (58–62). To assess this question
for CAD, Gola et al. (63) compared various methods from the
field of machine learning (ML), which offer attractive algorithms
to model non-linear effects, with a GPRS in a case-control data
set of samples of European descent from the German population.
It turned out that a simple GPRS outperformed all other
algorithms under consideration by means of a nested cross-
validation. However, the models differed greatly in the number of
variants used. While the GPRS utilized ~50,000 variants, the
non-linear models were much more sparse, utilizing
approximately 1,300 to 10,500 variants. The sheer number of
variants in GPRS is an aspect that should not be neglected for
their clinical utility: 1. Practical aspects. Although whole genome
sequencing becomes cheaper, processing of the data still requires
huge computational resources. Traditional genotyping arrays
provide a much cheaper and faster way to type variants.
However, customary arrays cover about 4.5 million variants,
much less than the 6.9 million variants used by Khera et al. 2.
Replication. The probability that all variants used by proposed
GPRS are available in independent datasets is almost zero. Thus,
imputation or proxy variants are necessary, making exact
replication of GPRS impossible. 3. Population bias. Using more
and more variants to construct GPRS results in overly population
specific models. It has already been shown that GPRS developed
in individuals of European descent cannot readily be applied to
other ethnic groups without taking into account the target
population’s structure (64). Yet, it is unknown whether the
performance of a GPRS utilising millions of variants depends
not only on ethnicity, but also on smaller genomic differences
within an ethnicity or even population.CLINICAL SEQUENCING AND ITS
IMPLICATION ON PRECISION MEDICINE
IN THE CLINICAL PRACTICE
Clinical Sequencing Directly Affects
Treatment of eoIBD Patients
The most important factors underlying IBD pathogenesis can be
summarized as genetics, environment, microbiome, and
immunome (indicating the dysregulation of the immune
response in the gut) (65). However, the genetic basis alone is
extremely complex: The susceptibility variants identified mainly
through GWAS explain only a fraction of the expected
heritability and most risk loci contain several candidate genes.
Only for selected loci, causal variants and genes have been
identified in the respective region. The genetic data fromJanuary 2021 | Volume 11 | Article 577677
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a certain subphenotype and therefore allow the prediction of
disease susceptibility and clinical phenotype up to a certain
degree. Today, the diagnosis of CD or UC patients still
primarily depends on endoscopy or colonoscopy, however,
there are also patients in whom CD and UC still cannot be
clearly distinguished leading to the unsatisfactory diagnosis of
IBD-U (IBD unclassified). Furthermore, IBD patients have an
extremely variable disease course, so the expectations for
precision medicine do not only include the improvement of
diagnostic methods but also the prediction of the disease course
and the optimal treatment strategy.
Predictive models based on the genetic risk score were able to
distinguish colonic from ileal Crohn’s disease (44). Additional
risk scores based on the microbiome may be possible in the
future (66) but are not advanced enough as of yet. A
transcriptional risk score based on summary-level GWAS and
expression quantitative trait locus (eQTL) data integrated with
RNA-seq data showed promising results: It outperformed genetic
risk scores for discriminating between CD patients and healthy
controls and was also able to predict disease course over time in
pediatric CD patients (67).
Early-onset forms of IBD highlight the exceptional potential for
precision medicine, since the identified variants can be functionally
characterized to understand the mechanisms and directly target the
disturbed pathways through therapy to correct the consequences of
the genetic defect. Thus, in a therapy-refractory IBD patient with a
genetic defect in the XIAP (X-linked inhibitor of apoptosis) gene
and in young children with defects of the IL10 pathway,
hematopoetic stem cell transplants (HSCT) were curative (68–71).
These examples show the significant progress that has been made
towards precision medicine in IBD, but they also highlight the
substantial challenges we are facing.Clinical Sequencing Enables Monitoring of
Established and Development of Novel
Treatment Strategies
Traditional treatment approaches for atopic dermatitis include
topical as well as systemic therapies. Progress in understanding
the pathophysiology of the disease facilitated the development of
novel targeted therapeutic options. One classical hallmark of AD
is the elevated expression of inflammatory cytokines, including
the interleukins IL‐4 and IL‐13, propagating the dysfunction of
the epidermal barrier. The monoclonal antibody Dupilumab
(Sanofi S.A.), targeting both cytokines represents the first
biologic agent approved for the treatment of AD (72). In a
recent study Guttman-Yassky et al. provide evidence for the drug
progressively improving disease activity, suppressing markers of
inflammation and reversing the typical epidermal abnormalities
(73). TREATgermany, a non-interventional multicenter patient
cohort study has been initiated to assess effectiveness and safety
of Dupilumab in the long term. Data collected at follow-up visits
of this ongoing study confirm high rates of response without
serious side effects (74). Tralokinumab (LEO Pharma A/S) and
Lebrikizumab (F. Hoffmann-La Roche AG) represent further
emerging treatment options. Tralokinumab, prevents IL‐13 fromFrontiers in Immunology | www.frontiersin.org 5binding to IL‐13Ra1 as well as IL‐13Ra2 (75). Lebrikizumab, in
turn, selectively targets IL-13 and interferes with the formation of
the IL-13Ra1/IL-4Ra receptor signaling complex (76). In
independent randomized, double-blind, placebo-controlled
phase 2b trials in participants with moderate-to-severe AD
both drugs showed clear improvements of AD symptoms and
an acceptable safety and tolerability profile.
Genetic Screening for Familial
Hypercholesteremia
Large-scale sequencing in a clinical setting is not widely established
for CAD, however in case of familial hypercholesteremia (FH)
genetic cascade screening is recommended by the World Health
Organization (WHO). Untreated FH significantly increases the risk
for atherosclerosis and premature CAD (77). Because of its high
prevalence and risk of severe complications, it is the only
cardiovascular disease recommended for population-based
screening by the WHO (78). Current recommendation endorses
lipid screening, however genetic testing is encouraged for family-
based cascade screening. Genetic testing is also useful to separate
heterozygous and homozygous cases, as well as to uncover potential
precision medicine targets (77). FH is mainly caused by variants in
genes coding for proteins affecting hepatic LDLC uptake including
the LDL receptor (LDLR), in which most disease-causing variants
are found, as well as apolipoprotein B-100 (APOB) and proprotein
convertase subtilisin/kexin type 9 (PCSK9). Multiple studies
document the preventive effect of intensive medical LDL-lowering
at young age to prevent cardiovascular events (78). Therefore, it has
been suggested that incidental detection of variants leading to FH
should be communicated to the affected individual and the family
(79). In fact, owing to the high frequency of FH, several guidelines
recommend programs to systematically unravel variants and to
facilitate medical treatment already at young age.PERSPECTIVES
Clinical sequencing has the potential to reveal directly actionable
genetic variants, thus also directly affecting treatment of the patient.
For some findings, treatment options already exist, such as HSCT
for defects in XIAP or the IL10 pathway and monoclonal antibodies
for directly targeting imbalanced metabolic processes. Novel
findings drive forward the development of new drugs by revealing
previously unknown pharmaceutical targets.
Cases reported within this review point to remaining
challenges in detecting disease-relevant variants (Table 1). For
example, the interpretation of synonymous and noncoding
variants is still difficult and can lead to false-negative results. A
possible complex interplay of rare and common variants, e.g., the
two variants in NOX1 and CYBA (3) makes the interpretation of
sequencing data even more difficult. Low coverage in genes of
interest can lead to reduced detectability of disease-related
variants and should therefore be considered with caution.
Finally, the choice of public databases represents another
crucial factor influencing the results of the analysis. Thus, it
needs to be acknowledged that frequency databases may containJanuary 2021 | Volume 11 | Article 577677
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like ClinVar and HGMD that try to classify variants may also
include errors, so variants listed as benign may still be potentially
pathogenic, as can be seen for the known Factor-V-Leiden
variant that was classified as benign by one submitter in
ClinVar. In summary, the greatest bottleneck for clinical
sequencing is still the interpretation of data and various factors
need to be kept in mind when using NGS data in diagnostics. In
the future, deeper sequencing, made possible through further
decreasing sequencing costs, novel analysis tools, and the
ongoing improvement of variant databases will allow for the
more widespread application of clinical sequencing.
The shift from gene panels to whole exomes is not yet complete.
Exome or whole genome sequencing still poses a challenge for small
diagnostic laboratories concerning infrastructural and bioinformatic
requirements resulting from the comparatively large volume of
generated data. However, the high potential of clinical sequencing is
reflected by the increasing rate of solved cases, ending the
“diagnostic odyssey” that many patients with rare disorders are
facing. Even if the identified genetic cause is not located in a gene
that can already be directly targeted in therapy and for which no
drugs exist yet, these findings help drive forward the development of
future drugs by revealing novel research targets.
While findings from GWAS and first WES studies lead to the
detection of loci being independently associated to the diseases,
their interplay has been barely investigated. Furthermore, it canFrontiers in Immunology | www.frontiersin.org 6be reasonably assumed that complementing genomic data
generated using sequencing technology by other omics layers
will help to achieve this objective. Due to their complexity,
inflammatory diseases are considered ideal targets for systems
biology approaches and integration of multi-omics data. Multi-
layered analyses combining, e.g., genomic, epigenomic and
transcriptomic data with the microbiome, immunome and
exposome are ideally suited to reveal the complex biology
underlying the diseases and to identify subphenotypes of the
diseases. This knowledge can then be used to develop the ideal
treatment, specifically tailored to the patient´s needs and disease
characteristics (Figure 1).
While the multi-omics approach is a promising strategy, due to
its complexity it is not yet feasible to be used in a clinical setting.
Likewise, risk prediction for complex inflammatory diseases is
complicated by the heterogeneity of each disease’s phenotype
and genetic architecture. Current polygenic risk scores therefore
do not yet meet the requirements for diagnosis in the clinical
setting. For a number of complex diseases, risk scores are utilized
in the stratification of patients in the setting of randomized
clinical trials, with the results likely to find their way into clinical
practice in the next decade. Thus, in the future, polygenic risk
scores may enable patient stratification early on after diagnosis
based on their genetic risk and allow for closer monitoring of
patients with a high genetic risk that are more prone to stronger
disease severity.FIGURE 1 | Polygenic risk scores represent promising tools for the stratification of patient groups. Incorporation of additional data from methomics, transcriptomics
and proteomics experiments might enable the derivation of multidimensional scoring schemes allowing a more accurate clustering of molecular disease phenotypes.
The identification of these disease subtypes might enable the elucidation of distinct disease pathogeneses and trajectories. Ultimately, it will allow custom strategies
for care and treatment of the individual patient.TABLE 1 | Challenges and possible solutions.
Challenges Possible solutions
Interpretation of synonymous and non-coding variants, complex
interplay of common and rare variants
- Ongoing developments of analysis/prediction tools taking into account findings from large
cohort sequencing studies
- Multi-omics approach combining, e.g., genomic, methylomic, transcriptomic and proteomic
data with the microbiome, immunome and exposome
Low coverage of relevant genomic regions - Deeper sequencing facilitated by a further decrease of sequencing costs
- Sequencing of exomes or genomes as a replacement for gene panels to include all potentially
relevant genomic regions
Large amounts of data from exomes and genomes overwhelm most
diagnostic laboratories
- Development of out-of-the-box infrastructural and bioinformatic solutions
Databases, such as ClinVar and HGMD, include questionable variant
classifications
- Critical handling and questioning of provided classifications
- Further expert curation of databases
Risk prediction for complex diseases complicated by heterogeneity of
phenotypes and genetic architecture
- Evaluation of impact of model type and complexity on the performance of PRS
- Ethnicity-specific large cohort studies for evaluation and optimization of PRS performanceThis table summarizes challenges of clinical sequencing in the context of inflammatory diseases as identified throughout this review and presents possible solutions.January 2021 | Volume 11 | Article 577677
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